Overview

Zanubrutinib in Patients With IgG4-Related Disease

Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in treating patients with IgG4-related disease
Phase:
Phase 2
Details
Lead Sponsor:
Matthew C. Baker
Collaborator:
Stanford University
Treatments:
Zanubrutinib